EXHIBIT 99.1 Galapagos reports first quarter 2024 financial results Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunology Executed agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier Medicines Transferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areas Group net revenues in the first quarter of €100 million Cash and c ...